Stoneridge Investment Partners LLC acquired a new position in Natus Medical Incorporated (NASDAQ:BABY) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 23,043 shares of the medical equipment provider’s stock, valued at approximately $860,000.

Several other hedge funds have also made changes to their positions in the company. State of Alaska Department of Revenue raised its stake in shares of Natus Medical by 1.7% in the first quarter. State of Alaska Department of Revenue now owns 3,630 shares of the medical equipment provider’s stock worth $142,000 after buying an additional 60 shares in the last quarter. Louisiana State Employees Retirement System raised its stake in shares of Natus Medical by 0.7% in the second quarter. Louisiana State Employees Retirement System now owns 13,500 shares of the medical equipment provider’s stock worth $504,000 after buying an additional 100 shares in the last quarter. Municipal Employees Retirement System of Michigan raised its stake in shares of Natus Medical by 1.5% in the first quarter. Municipal Employees Retirement System of Michigan now owns 7,520 shares of the medical equipment provider’s stock worth $295,000 after buying an additional 110 shares in the last quarter. Arizona State Retirement System raised its stake in shares of Natus Medical by 1.2% in the first quarter. Arizona State Retirement System now owns 17,106 shares of the medical equipment provider’s stock worth $671,000 after buying an additional 200 shares in the last quarter. Finally, Intrust Bank NA raised its stake in shares of Natus Medical by 3.7% in the first quarter. Intrust Bank NA now owns 8,229 shares of the medical equipment provider’s stock worth $323,000 after buying an additional 295 shares in the last quarter. 93.86% of the stock is currently owned by institutional investors and hedge funds.

Natus Medical Incorporated (NASDAQ:BABY) opened at 33.10 on Friday. The firm has a market capitalization of $1.08 billion, a P/E ratio of 57.37 and a beta of 0.93. The company’s 50-day moving average is $36.51 and its 200-day moving average is $36.73. Natus Medical Incorporated has a one year low of $32.83 and a one year high of $44.39.

Natus Medical (NASDAQ:BABY) last issued its quarterly earnings data on Wednesday, July 26th. The medical equipment provider reported $0.34 earnings per share for the quarter, beating the consensus estimate of $0.33 by $0.01. Natus Medical had a return on equity of 12.09% and a net margin of 4.20%. The business had revenue of $122.20 million for the quarter, compared to analysts’ expectations of $121.99 million. During the same period last year, the business earned $0.39 EPS. The business’s revenue was up 27.3% on a year-over-year basis. Equities analysts forecast that Natus Medical Incorporated will post $1.70 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Stoneridge Investment Partners LLC Invests $860,000 in Natus Medical Incorporated (BABY)” was published by Daily Political and is owned by of Daily Political. If you are reading this story on another domain, it was copied illegally and republished in violation of United States & international trademark & copyright legislation. The legal version of this story can be accessed at https://www.dailypolitical.com/2017/08/11/stoneridge-investment-partners-llc-invests-860000-in-natus-medical-incorporated-baby.html.

A number of brokerages recently weighed in on BABY. Benchmark Co. restated a “buy” rating and set a $48.00 target price (down from $55.00) on shares of Natus Medical in a report on Monday, May 1st. Zacks Investment Research downgraded shares of Natus Medical from a “hold” rating to a “sell” rating in a report on Friday, April 28th. BidaskClub upgraded shares of Natus Medical from a “sell” rating to a “hold” rating in a report on Saturday, July 1st. Finally, TheStreet downgraded shares of Natus Medical from a “b” rating to a “c+” rating in a report on Thursday, April 27th. Three analysts have rated the stock with a sell rating, two have assigned a hold rating and one has assigned a buy rating to the stock. The company currently has an average rating of “Hold” and an average target price of $45.00.

In other Natus Medical news, Director Doris Engibous sold 5,000 shares of the firm’s stock in a transaction on Thursday, May 25th. The stock was sold at an average price of $32.68, for a total transaction of $163,400.00. Following the transaction, the director now directly owns 22,650 shares in the company, valued at approximately $740,202. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider James B. Hawkins acquired 4,000 shares of the company’s stock in a transaction on Thursday, June 15th. The shares were bought at an average price of $33.98 per share, for a total transaction of $135,920.00. Following the completion of the purchase, the insider now owns 578,023 shares in the company, valued at approximately $19,641,221.54. The disclosure for this purchase can be found here. 5.50% of the stock is currently owned by company insiders.

About Natus Medical

Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.

Want to see what other hedge funds are holding BABY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natus Medical Incorporated (NASDAQ:BABY).

Institutional Ownership by Quarter for Natus Medical (NASDAQ:BABY)

Receive News & Ratings for Natus Medical Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.